SEARCH

SEARCH BY CITATION

References

  • 1
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302308.
  • 2
    Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; CD003559.
  • 3
    Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149153.
  • 4
    Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:17651776.
  • 5
    Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114:265269.
  • 6
    Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120:11461152.
  • 7
    Campbell JD, Spackman DE, Sullivan SD. Health economics of asthma: assessing the value of asthma interventions. Allergy 2008;63:15811592.
  • 8
    Campbell JD, Spackman DE, Sullivan SD. Revisiting the cost-effectiveness of omalizumab. Allergy 2007;62:1469.
  • 9
    Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008;63:670684.
  • 10
    Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108:3946.
  • 11
  • 12
    Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309316.
  • 13
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701708.
  • 14
    Sullivan SD, Eisner MD, Campbell JD, Omachi TA. Risk of Mortality Associated with Asthma Exacerbation. San Diego CA: ATS 2009.
  • 15
    National Heart Lung and Blood Institute. Morbidity and Mortality: 2002 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: US Department of Health and Human Services; 2002.
  • 16
    Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:7683.
  • 17
    Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference- based single indicies from non-preference based condition-specific instruments: converting AQLQ into EQ-5D indices. The University of Sheffield, School of Health and Related Research, Sheffield Health Economics Group Discussion Paper Series 02/1, May 2002. (N = 3880 subject visits).
  • 18
    EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990;16:199208.
  • 19
    Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Resp J 2004;13:113.
  • 20
    MarketScan Databases 2006. [cited 2007 September 7]; Available from: http://www.medstat.com/products/productdetail.aspx?id=71.
  • 21
    CPT Search. 2009 [cited 3/6/09]; Available from: https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?locality=AA.
  • 22
    Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC et al. Good research practices for measuring drug costs in cost effectiveness and analyses: issues and recommendations: the ISPOR drug cost task force report-Part I. Value Health 2010;13:813.
  • 23
    The Zitter Group. Zitter Managed Care Injectables Index. Fall 2008.
  • 24
    United States Department of Labor Bureau of Labor Statistics. Inflation Calculator.
  • 25
    Watkins JB, Choudhury SR, Wong E, Sullivan SD. Managing biotechnology in a network-model health plan: a U.S. private payer perspective. Health Aff (Millwood) 2006;25:13471352.
  • 26
    Ayre G, Fox H, Chen H et al. Evaluating response to omalizumab (anti-IgE) in clinical practice. Poster presented at the European Respiratory Society Meeting, 17–21 September 2005; Copenhagen.
  • 27
    Gold MR, Siegel JE, Russell LB, Wienstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford Press Inc, 1996.
  • 28
    Carranza RosenzweigJR, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 2004;98:11571165.
  • 29
    Martin TG, Elenbaas RM, Pingleton SH. Failure of peak expiratory flow rate to predict hospital admission in acute asthma. Ann Emerg Med 1982;11:466470.
  • 30
    Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma: National Heart, Lung, and Blood Institute. national Asthma Education and Prevention Program (NAEPP); 2007.
  • 31
    Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:11391151.
  • 32
    Krasnick J, Patterson R, Harris KE. Idiopathic anaphylaxis: long-term follow-up, cost, and outlook. Allergy 1996;51:724731.
  • 33
    Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003;112:12291236.